Yoko Fukuda, MD
Hematology & Oncology · Portsmouth, NHNPI 1568622801
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $788 of the $1,196 with a category attached, or 65.9%. It is spread thinly across 17 manufacturers, the largest accounting for just 20.4%.
Across 51 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$244
- Genentech USA, Inc.$176
- Johnson & Johnson$129
- AbbVie$119
- AstraZeneca$83
- Pharmacyclics LLC, An Abbvie Company$67
- plus $379 from 11 others
Across 1 payment — averaging $2544.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Food & beverage$78866%
- Education$40834%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 19 | $244 |
| Genentech USA, Inc. | 2 | $176 |
| Johnson & Johnson(2 entities) | 3 | $129 |
| AbbVie | 4 | $119 |
| AstraZeneca | 3 | $83 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $67 |
| Incyte Corporation | 3 | $66 |
| Amgen | 1 | $65 |
| Pfizer | 3 | $52 |
| Rigel Pharmaceuticals, Inc. | 2 | $50 |
| Seagen Inc. | 2 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$1,196 in reported general payments places this provider in the 85th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 25 | $575,957 |
| CalquenceAcalabrutinib Maleate | 36 | $438,068 |
| RevlimidLenalidomide | 22 | $422,793 |
| Lenalidomide | 23 | $296,697 |
| XtandiEnzalutamide | 18 | $259,950 |
| IbrancePalbociclib | 13 | $193,764 |
| BrukinsaZanubrutinib | 22 | $179,570 |
| EliquisApixaban | 110 | $105,441 |
| Fondaparinux Sodium | 12 | $23,999 |
| XareltoRivaroxaban | 22 | $14,166 |
| Exemestane | 23 | $2,979 |
| Letrozole | 82 | $2,570 |
| Hydroxyurea | 74 | $1,756 |
| Tamoxifen Citrate | 55 | $1,305 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $1,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $21 | $575,95725 claims |
| AstraZenecaCalquence | $83 | $438,06836 claims |
| PfizerIbrance, Eliquis | $52 | $299,205123 claims |
| Johnson & JohnsonXarelto | $129 | $14,16622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 hematology & oncology providers in New Hampshire.
Other hematology & oncology in Portsmouth
- Elena TheodosiouPortsmouth$300
- Wilhelmina CabalonaPortsmouth$170
- Jonathan ProulxPortsmouth$131
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Nancy ChunNashua$7K
- Amy BessnowDover$6K
- Konstantin DragnevLebanon$5K
- Keisuke ShiraiLebanon$5K
- Eric LubinerNorth Conway$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.